S. Laurent

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

Philippe A. Cassier, Gwenaëlle Garin, Lauriane Eberst et al. · Journal of Clinical Oncology · 2019 · 48 citations

Medicine, Oncology, Pharmacology +17

Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC)

Sabine Tejpar, Eric Van Cutsem, Érick Gamelin et al. · Journal of Clinical Oncology · 2004 · 30 citations

Medicine, Oncology, Pharmacology +17

Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC)

Sabine Tejpar, Eric Van Cutsem, Érick Gamelin et al. · Journal of Clinical Oncology · 2004 · 11 citations

Medicine, Oncology, Pharmacology +17